GEXVal Inc.
GEXVal, a Japan-based clinical-stage biopharma founded as a Takeda Pharmaceutical spin-off, tackles “Access to Medicine” issues in rare diseases and underserved medical conditions. As innovative ‘Drug Hunters’, we focus on pharma-originated high-value drug candidates for preclinical proof-of-concept (POC), swiftly progressing to clinical POC before licensing for late-stage development and commercialization.
Our strength lies in a global virtual team of seasoned pharma professionals, each averaging over 30 years of industry experience across various therapeutic areas. RePhaIND™, our proprietary AI-assisted pharmacoinformatics tool, drives innovation by uncovering hidden links between compounds, mechanisms, and diseases.
Our lead compound, GXV-001, originated from Takeda, is well differentiated from existing therapeutic approaches for its potential to modulate neurobehavioral and cognitive disorders by unique triple action for neuroprotection-balancing neurotransmitters and inducing neurotrophic factors, protection from BBB destruction, and neuroinflammation. Just completed Phase 1 and confirmed proof-of-mechanism. It is now ready for two pivotal POC studies: one in a rare neurobehavioral disease and another in more prevalent cognitive disorder with shared underlying mechanisms. First in-patient study targets post-operative delirium, addressing a significant unmet need in our super-aging society. GEXVal envisions a brighter future: a society free from delirium and dementia, embracing longevity.
